[锆]曲妥珠单抗：HER2阳性乳腺癌女性患者的放射剂量测定、安全性及最佳成像参数评估
[Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.
作者信息
Laforest Richard, Lapi Suzanne E, Oyama Reiko, Bose Ron, Tabchy Adel, Marquez-Nostra Bernadette V, Burkemper Jennifer, Wright Brian D, Frye Jennifer, Frye Sarah, Siegel Barry A, Dehdashti Farrokh
机构信息
Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Mol Imaging Biol. 2016 Dec;18(6):952-959. doi: 10.1007/s11307-016-0951-z.
PURPOSE
The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [Zr]trastuzumab in patients with HER2-positive breast cancer.
PROCEDURES
Twelve women with HER2-positive breast cancer underwent [Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model.
RESULTS
High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [Zr]trastuzumab were encountered.
CONCLUSION
[Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
目的
本研究旨在评估[锆]曲妥珠单抗在HER2阳性乳腺癌患者中的安全性、人体辐射剂量测定及最佳成像时间。
程序
12名HER2阳性乳腺癌女性患者在注射后7天内接受了两次[锆]曲妥珠单抗正电子发射断层扫描（PET）/X射线计算机断层扫描（CT）。利用所有患者的数据生成了全身体PET/CT图像的生物分布数据和器官时间-活度曲线。使用OLINDA和成年女性模型计算人体剂量。
结果
注射后5±1天进行的图像获得了高质量图像以及最大的肿瘤与非肿瘤对比度。10名患者中至少有一个已知病灶处可见[锆]曲妥珠单抗摄取增加。肝脏是剂量限制器官（摄取约12%的注射剂量，平均剂量为1.54 mSv/MBq）。有效剂量为0.47 mSv/MBq。未发现[锆]曲妥珠单抗的不良反应。
结论
[锆]曲妥珠单抗在注射后至少4天是安全的且成像效果最佳。肝脏是剂量限制器官。
Zotero 插件